Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with ...

The majority of working-age patients with postacute sequelae of COVID-19/PCS do not recover in the second year of their illness.

Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

President Trump has ended a Biden administration effort to lower the cost of prescription drugs for people on Medicare and Medicaid.

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.

On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.